Abstract Background Alpha-1-fetoprotein (AFP) is used to monitor progression, evaluate
response to therapy and predict recurrence of hepatocellular carcinoma (HCC) in liver …

We aimed to determine whether combining serum alpha‐fetoprotein (AFP) level with
hepatocellular carcinoma (HCC) tumor burden would allow better stratification of …

Background Many patients with hepatocellular carcinoma (HCC) who undergo liver
transplantation (LT) subsequently develop tumor recurrence; this is the main factor affecting …

Growing evidence suggests that pretransplant alpha‐fetoprotein (AFP) predicts outcomes of
hepatocellular carcinoma (HCC) patients treated with liver transplantation. We aimed to …

Alpha-fetoprotein (AFP) is the main tumor biomarker available for the management of
hepatocellular carcinoma (HCC). Although it is neither a good screening test nor an …

The role of alpha-fetoprotein (AFP) in the specific setting of the diagnosis and prognosis of
patients with hepatocellular cancer (HCC) waiting for liver transplantation (LT) is still …

Background Although liver transplantation may potentially cure hepatocellular carcinoma
(HCC), the risk of HCC recurrence is 8%‐20% at five years post‐transplant. Pre‐transplant …

Pretransplant alpha-fetoprotein (AFP) is a useful tumor marker predicting recurrence of
hepatocellular carcinoma (HCC). Little is known, however, about the relationship between …

Background & Aims Alpha-fetoprotein (AFP) predicts hepatocellular carcinoma (HCC)
recurrence after liver transplant (LT) but remains an imperfect biomarker. The role of DCP …

Hypothesis An elevated serum α-fetoprotein (AFP) level before orthotopic liver transplant
(OLT) is predictive of mortality after OLT for hepatocellular carcinoma (HCC). Design …